The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N04 | Anti-parkinson drugs | |
| 3 | N04B | Dopaminergic agents | |
| 4 | N04BX | Other dopaminergic agents | |
| 5 | N04BX02 | Entacapone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1 g |
| Active Ingredient | Description | |
|---|---|---|
| Entacapone |
Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| COMTAN Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| MEDAPIA Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
